[1] Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet, 2014, 383: 1749-1761. [2] Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol, 2014, 14: 181-194. [3] Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature Rev Immunol, 2004, 4:583-594. [4] 李妍,陆伦根. 肝纤维化的分子基础与临床诊治现状. 临床肝胆病杂志, 2018, 34: 12-15. [5] 王林, 刘学恩, 庄辉. 多种细胞在肝纤维化逆转中的作用. 临床肝胆病杂志, 2018, 34:862-866. [6] Faggioli F, Palagano E, Di Tommaso L, et al. B lymphocytes limit senescene-driven fibrosis resolution and favour hepatocarcinogenesis in mouse liver injury. Hepatology, 2018, 67: 1970-1985. [7] Karlmark KR, Weiskirchen R, Zimmermann HW, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promoteshepatic fibrosis. Hepatology, 2009, 50:261-74. [8] Karlmark KR, Wasmuth HE, Trautwein C, et al. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepato, 2008, 2:233-42. [9] Pérez-Cabeza de Vaca R, Domínguez-López M, Guerrero-Celis N, et al. Inflammation is regulated by the adenosine derivative molecule, IFC-305, during reversion of cirrhosis in a CCl4 rat model. Int Immunopharmacol, 2018, 54:12-23. |